Compare Honeywell International Inc (HON) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Johnson & Johnson — how do they compare? Honeywell International Inc trades at $208.15 (market cap $65.48B), while Johnson & Johnson trades at $261.05 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 9.4× Honeywell International Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Johnson & Johnson for 129 Days on average.
| HON | JNJ | |
|---|---|---|
Market Cap | $65.48B | $618.09B |
Volume | 2,047,782 | 6,050,983 |
Sector | Industrials | Health |
52-Week High | $248.79 | $278.43 |
52-Week Low | $188.14 | $186.00 |
Typical Hold Time | 90 Days | 129 Days |
Enterprise Value | $90.27B | $646.37B |
Dividend Yield | 1.36% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.11, down 2.24% on the day, with a bearish technical signal from moving averages but strong fundamentals including a low P/E of 7.94 and robust ROE of 47.43%. Recent earnings beats and a $300 million refinery project win highlight operational strength, while the company's post-spin focus on automation drives growth expectations.
The outlook is positive with a consensus price target of $259.25 implying 24.6% upside, supported by analyst bullishness (66.7% buy ratings). Risks include rising debt-to-asset ratios and cyclical exposure, but solid cash flow and dividend payments provide stability amid near-term volatility.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
